Squamous Cell Carcinoma of the Head and Neck
Oncology·MeSH: Squamous Cell Carcinoma of Head and Neck
Prevalence
14.0 / 100K
Incidence
6.0 / 100K/yr
13 drugs in development·7 companies·14 clinical trials
Drug Pipeline by Phase
Phase 3(5)
Phase 2(1)
| Drug | Company |
|---|---|
| cylembio | IO Biotech, Inc. (IOBT) |
Phase 1(6)
Phase 4(1)
| Drug | Company |
|---|---|
| Monalizumab | ASTRAZENECA PLC (AZN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Squamous Cell Carcinoma of the Head and Neck?
BioSniper tracks 13 drugs in development for Squamous Cell Carcinoma of the Head and Neck across 7 companies.
How many clinical trials target Squamous Cell Carcinoma of the Head and Neck?
There are 14 clinical trials targeting Squamous Cell Carcinoma of the Head and Neck tracked by BioSniper.
What is the prevalence of Squamous Cell Carcinoma of the Head and Neck?
The estimated prevalence of Squamous Cell Carcinoma of the Head and Neck is approximately 14.0 per 100,000 population.
Deep-dive into Squamous Cell Carcinoma of the Head and Neck
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis